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Background: The treatment of cancer associated thrombosis (CAT) is well established, with level 1A evidence to
support the recommendation of a low molecular weight heparin (LMWH) by daily injection for 3–6 months.
However, registry data suggest compliance to clinical guidelines is poor. Clinicians face particular challenges in
treating CAT in advanced cancer patients due to shorter life expectancy, increased bleeding risk and concerns that
self injection may be too burdensome. For these reasons decision making around the diagnosis and management
of CAT in people with advanced cancer, can be complex, and should focus on its likely net benefit for the patient.
We explored factors that influence doctors’ decision making in this situation and sought to gain an understanding
of the barriers and facilitators to the application of best practice.
Methods: Think aloud exercises using standardised case scenarios, and individual in depth interviews were
conducted. All were transcribed. The think aloud exercises were analysed using Protocol Analysis and the interviews
using Framework Analysis.
Participants: 46 participants took part in the think aloud exercises and 45 participants were interviewed in depth.
Each group included oncologists, palliative physicians and general practitioners and included both senior doctors
and those in training.
Setting: Two Strategic Health Authority regions, one in the north of England and one in Wales.
Results: The following key issues arose from the data synthesis: the importance of patient prognosis; the concept
of “appropriateness”; “benefits and burdens” of diagnosis and treatment; LMWH or warfarin for treatment and
sources of information which changed practice. Although interlinked, they do describe distinct aspects of the
factors that influence doctors in their decisions in this area.
Conclusions: The above factors are issues doctors take into account when deciding whether to send a patient to
hospital for investigation or to anticoagulate a patient with confirmed or suspected VTE. Many factors interweave
and are themselves influenced by and dependent on each other. It is only after all are taken into account that the
doctor arrives at the point of referring the patient for investigation. Some factors including logistic and
organisational issues appeared to influence whether a patient would be investigated or treated with LMWH for a
confirmed VTE. It is important that services are optimised to ensure that these do not hinder the appropriate
investigation and management of individual patients.
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Venous thromboembolism (VTE) such as deep vein
thrombosis (DVT) or pulmonary embolism (PE) occurs
in 1 in 1000 patients and globally affects 6.5 million
people annually [1,2]. It is particularly common in
patients with cancer and the incidence appears to in-
crease with disease progression. Approximately one sixth
of cancer patients will have symptoms due to VTE [3,4]
and one study in advanced cancer patients indicated
revealed over half to have evidence of DVT on routine
testing [5]. The treatment of VTE usually consists of 3
to 6 months anticoagulation with warfarin [6-12], but
this regime is associated with high bleeding complica-
tions and recurrent thromboses in cancer patients
[13,14]. Three randomised controlled trials have demon-
strated low molecular weight heparin (LMWH) to be su-
perior to warfarin in the management of cancer
associated thrombosis (CAT) and LMWH is now recom-
mended as the anticoagulant of choice in patients with
malignant disease [9,11,12,14-18].
The management of VTE in patients with advanced
cancer pose particular challenges for doctors [19,20].
Firstly, the complications of bleeding and recurrent
thrombosis are likely to be greater than in the general
cancer population. Second the data informing VTE
guidelines in cancer patients contained few patients of
poor performance status or short prognosis. Finally clin-
ical decision making can be complex in patients for
whom the focus of treatment is palliative, but who are
not imminently dying [20] since best care will focus on
control of symptoms and maintaining quality of life ra-
ther than treating a clinical condition at all costs.
Data from a national venous thromboembolism regis-
try (Verityonline) suggest the use of LMWH is not rou-
tinely used in cancer patients suggesting a disparity
between clinical practice and the evidence [21]
Existing literature has highlighted that knowledge of
research evidence is rarely enough by itself to change
practice [22,23]. The factors affecting practitioners’ deci-
sion making behaviour can vary from individual charac-
teristics (such as lack of knowledge about the evidence),
patient factors (complexities associated with advanced
disease), through to organisational aspects (such as lack
of facilities or equipment). The implementation of evi-
dence based guidelines is often carried out uncritically,
with little consideration of the issues which may encour-
age doctors to change their behaviour, or consideration
of implementation strategies that may be the most ap-
propriate for a specific clinical context.
There is currently little evidence examining the factors
that influence clinicians’ decision making surrounding
the management of patients with advanced cancer and
VTE. A vital step towards improving patient care there-
fore, is to explore how doctors make clinical decisions,and to understand the barriers to and facilitators for the
application of best practice guidelines within the context
of broader organisational culture and policy initiatives.
In this paper we report the key findings of a study
designed to address the following research questions:
1. How do medical practitioners currently make
decisions about the treatment of patients with VTE
and advanced cancer?
2. What are the barriers and facilitators to change with
regard to the implementation of current best practice
in patients with advanced cancer and VTE?
3. What strategies would be most effective for
implementing best practice evidence in these
patients?
Methods
We addressed the research questions using a combin-
ation of think aloud protocols and individual semi-
structured interviews. In the first stage we focussed on
doctors’ decision-making processes using a think aloud
method. In the second stage we investigated the experi-
ence of the participants, to explore the barriers and facil-
itators to good practice in the diagnosis and
management of people with advanced cancer and VTE
using in-depth individual interviews.
NHS Research Ethics and Research Governance
approvals were obtained prior to the commencement of
each stage.
Think aloud study
Think aloud is a method commonly used to explore the
cognitive processes used by individuals when making
decisions. Study participants were asked to verbalise
their thoughts when presented with clinical case scenar-
ios ranging in length and complexity. Think aloud
assumes that the subjects’ verbalisations represent the
thought processes that they are using whilst making a
decision [24]. This approach enabled us to examine the
information clinicians used to inform their decisions, to-
gether with the nature of decisions taken in relation to
the diagnosis and treatment of VTE and cancer.
Six case scenarios were derived for the study by clini-
cians in the project team (MJ, SN, AM), drawing on
their expertise and clinical experience of managing
patients with advanced cancer and VTE. Scenarios were
presented in the form of a clinical record to represent
the information available to the clinician in practice as
closely as possible. It is important to make the cases as
realistic as possible as clinician performance on a deci-
sion task has been found to be ‘task specific’ [24]. The
scenarios covered a range of specific decisions and situa-
tions in patients with cancer; variation in prognosis, clin-
ical severity of the suspected episode of VTE, age, sex
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face and content validity with a panel of clinical experts
and modified accordingly, drawn from oncologists, pal-
liative care physicians and general practitioners (n = 4),
identified by members of the research team, and their
feedback incorporated.
During the think aloud task, participants received a
standard introduction to the study by the researchers.
This explained the methodology of think aloud, reas-
sured the participants of strict confidentiality and clearly
stated that the think aloud exercise was not a test which
had ‘right or wrong’ answers. Participants were asked to
read the scenarios a few sentences at a time and verbal-
ise their immediate thoughts about the presented case
out loud. Additional information about the cases was
available from the researcher if requested by the partici-
pant. Participants were not asked to define a treatment,
as we wished to explore whether treatment for each case
scenario would be part of what the participant ‘thought
aloud’ using their own decision making process or not.
During silences, the researchers prompted participants
to keep thinking aloud, but no specific additional direc-
tion was given.
Semi-structured interviews
In-depth interviews were developed from themes arising
from the initial analysis of the think aloud data together
with a focus on the known barriers and facilitators to
practice around VTE and cancer. Questions focussed on
barriers to practice for VTE in cancer patients and
centred on: anticoagulation; diagnosis & treatment of
VTE; logistical, clinical, institutional or attitudinal issues;
positive facilitators to their practice. Questioning was
adaptive to the responses of the participants.
The topic guide was restructured and amended
throughout the fieldwork as new themes emerged.
All participants provided written, informed consent
prior to taking part in the study, which included explicit
permission for the use of anonymised verbatim quota-
tions in dissemination. Participant anonymity was
ensured by the use of study identification number.
Sample
Participants for both stages of the study were purpos-
ively sampled by specialty (oncology, palliative medicine
or GP) and grade, in order to seek diversity of opinion
according to experience and focus of practise. These
three groups were chosen because all may be involved in
the diagnosis and management of patient with advanced
cancer and VTE. Although GPs may be less involved
with initiating treatment, they will be involved in deci-
sions regarding investigation and continuation of treat-
ment in the community. We recruited participants from
two regions of the UK, one in the North of England andthe other in Wales. Seventy percent of those taking part
in the think aloud study also agreed to an in depth inter-
view; the remainder of the participants who were inter-
viewed were recruited by snowball sampling, to
maximize sample variation in the sample. Participants
practised across a geographically broad spectrum in both
sites, representing both urban and rural areas. Oncolo-
gists were recruited from two large teaching hospitals,
two oncology hospitals and two district general hospi-
tals. Palliative medicine doctors worked across acute
hospitals and a wide range of hospices (some partici-
pants had a dual hospital/hospice role).
The sample size in the interview study was determined
from previous studies as likely to provide adequate data
to gain in-depth insights into clinicians’ decision pro-
cesses [25].
Data collection
Potential participants were identified via registers in the
public domain and regional Deaneries. They were sent
an invitation letter outlining the purpose of the study
and those interested in taking part were contacted for
the necessary consent and interview arrangements. Data
collection was mostly conducted at the participants’
place of work although a minority of participants were
interviewed in their home. Fieldwork was conducted by
non-clinical experienced researchers (LS & HP) in order
to prevent the “dual role” that can occur when qualita-
tive work is conducted by clinician researchers, and in
particular to minimise the risk that participants could
perceive the think aloud study as a test of knowledge
thus reducing the likelihood that the participants give an
unbiased reflection of their actual practice. This was par-
ticularly important as three of the research team are
considered to be opinion leaders and this may have been
known by some respondents. Participants were reas-
sured that all data would be anonymised.
Fieldwork for the think aloud study took place be-
tween March and August 2010 and between September
2010 and January 2011 for the interview study. All think
aloud exercises and semi-structured interviews were
digitally recorded and transcribed for analysis.
Data analysis
All data were managed using the software package
Atlas-ti.
Think aloud study
Think aloud transcripts were analysed using protocol
analysis to identify the information and specific cognitive
processes involved in individual decision making
[24,26,27]. Verbalisations were segmented into codes
representing elements of identified thought processes;
using a coding framework adapted from Twycross &
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work was developed by DD, LS and HP and resulted in
the following codes: Collect, Interpret, Clinical Evalu-
ation, Social Evaluation, Plan, Reason, Opinion, Diag-
nose, Goal (Appendix A). Every transcript was coded by
LS and then DD and HP each double coded a half of the
dataset. All disagreements between first and second cod-
ing were marked up and consensus was reached through
discussion. Every sentence was coded into one or more
of the codes listed above with many sentences having
multiple coding attributed to them. The main codes
related to reasoning were Plan, Reason & Clinical Evalu-
ate. These codes were closely scrutinised to ascertain
doctors decision making processes.
Interview study
Interview data were analysed using the five stages of
Framework Analysis [25] via a process of; familiarisation,
identifying a thematic framework, indexing, charting and
finally mapping and interpretation. DD and LS inde-
pendently scrutinised the same six transcripts which
were selected for maximum variation. Both individuals
devised draft coding frameworks, which were then com-
pared to devise an initial coding framework based on
comparable themes. Further iterations of the framework
occurred as coding progressed, through discussion be-
tween DD and LS and then through the wider forum of
the project management group and subsequent revision.
Data synthesis
Following initial coding of both elements of the study an
initial description of key issues was produced. DD and
LS then mapped each of the elements of the individual
analyses to identify commonalities and discrepancies in
issues and themes arising out the data. A conceptual
framework was produced to provide an overview of the
data mapping, providing a synthesis of data from both
elements of the study.
Results
Forty six clinicians, aged between 28 – 61 years, (22
women; 24 men) participated in the think aloud study.
All three specialties were represented, (15 oncologists;
16 palliative physicians; 15 GPs) and each group had a
mixture of senior and junior doctors. Forty five clini-
cians (26 women, 19 men) were interviewed, ranging in
age from 28 to 58 years. Each specialty group had a mix-
ture of junior and senior doctors. More oncologists
(n = 20) were interviewed than palliative physicians
(n =15) or GPs (n = 10), as data saturation was reached
earlier in the latter two groups.
Analysis of the think aloud data identified 11 codes re-
lating to doctors’ engagement in a decision making strat-
egy. The codes reflected different stages of the decisionprocess related to information use, reasoning processes
used and the rationale or goal of the decision process
(Appendix A). Coding Framework for Think Aloud
Interview. Five themes arose out of the analysis of the
interview data; 1) logistical & organisational issues (split
between investigation & treatment), 2) ethical frame-
works & the concept of appropriateness, 3) patient &
disease specific factors and 4) knowledge, evidence & ex-
perience which doctors used to formulate decisions and
5) VTE risk assessment and prophylaxis.Framework overview
Synthesis of the data suggested that there were two dis-
tinct decision phases that occur when a clinician is faced
with an individual who has cancer and a potential VTE.
The first phase involved an assessment of the likelihood of
VTE and whether or not to send the patient for a diagnos-
tic test, and if so what test might be appropriate. The sec-
ond phase, if they decided that the patient did have a
VTE, was a consideration whether or not to treat it, and if
so, the relative benefits/burdens of LMWH over Warfarin.
Factors that influenced the decisions taken included clini-
cians’ evaluation of the patient’s prognosis (stage of ill-
ness), the appropriateness of intervening, logistical and
organisational issues associated with intervening and
patient’s preferences. The discussion of these factors was
multi-dimensional and complex. We used two methods to
address the research question, in order to gain insights
into the cognitive processes and personal experience of
participants. For ease of discussion in this paper we
present findings from the think aloud study and the inter-
view study separately discussing each influencing factor in
relation to the different decision phases where applicable,
before providing a summary of the main issues.Think aloud findings
Clinical evaluation underpins decisions about investigation
and treatment
One of the main cognitive activities engaged in by clini-
cians was evaluation of the risks from the VTE, possible
treatment options of the VTE and the underlying cancer –
especially if this was extensive and likely to result in a poor
prognosis for the patient. However, opinion was divided
about the relative merits of each, and different conclusions
regarding management plans were seen. Much of the risk/
benefit balance considered was a clinical evaluation, related
to the patient’s clinical condition (e.g. likelihood of VTE).
However, GPs and palliative physicians were also more
likely to take into account the contributory social issues,
such as distance to the hospital, and the impact on depen-
dants such as small children; these issues were carefully
considered. Summaries of the scenarios referred to in this
section can be found in Appendix B. Scenario summaries.
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bleeding into her brain tumour I suppose is something
to consider but even that she has a confirmed PE it
will be very difficult not to treat it but it is something
that we have to let the patient and the family know
that there is a risk of her bleeding into the tumour and
potentially that will be very detrimental to her life
expectancy if she does bleed into the tumour, her life
expectancy is not very good anyway.” (Oncology
registrar, England, ID17, scenario 5)
“He needs an urgent, urgent scan of his leg, mega
urgent and I think these children are potentially
vulnerable because he could die today. I think this is a
mega priority case and basically he’s got a massive
DVT until proved otherwise and he’s going to need to
be anticoagulated and the big problem is the children
and he should not be alone either because if he has a
massive PE, he’ll die in front of the children when
there’s nobody there.” (Palliative medicine consultant,
Wales, ID10, scenario 2)
Plans for investigation or treatment and their reasons
Interwoven with evaluations of the patient’s condition
were plans regarding investigation and treatment and
the rationale for that plan (coded as a reason). Although
there were similar processes used with regard to weigh-
ing up patient risk and benefit, the plans made could
vary between doctors. Most variation centred on
whether to investigate or not, whether to anticoagulate
or not, and if so which anticoagulant to use. The follow-
ing two doctors from the same specialty, at the same
training grade came to opposite conclusions.
“There is the risk, somebody with brain mets, that if
we gave the Clexane there is an increased risk of
having a bleed in the brain but it’s not an absolute
contraindication because there is nothing to say that
on the scan there were signs of bleeding, so I think
given that she’s now acutely unwell with confirmed
bilateral pulmonary emboli, I would, from a best
interest point of view, see treating those as a priority
over the risk of the brain mets bleeding really.”
(Palliative medicine registrar, Wales, ID8, scenario 5)
“I don’t think I would recommend anticoagulation
really. I don’t think it’s likely to help her. I don’t think
it will prolong her life probably. I don’t think it will
particularly help her symptoms either. . . possibly
make her bleed into her brain.” (Palliative medicine
registrar, England, ID5, scenario 5)
The scenarios generated differing opinions as to which
anticoagulant to use. In all scenarios, if anticoagulationwas planned, warfarin was more likely to be chosen by
GPs than by oncologists or palliative physicians. All the
palliative physicians and most of the oncologists plan-
ning to anticoagulate planned to use LMWH alone. A
minority of oncologists planned to use initial LMWH
followed by warfarin. Reasons for choosing LMWH
included the ease of control of anticoagulation and
knowledge that it is more effective in cancer.
“In terms of how I would anticoagulate her, I would
be inclined with this sort of patient to probably go
with low molecular weight heparin rather than
Warfarin, it’s just more controllable. . .” (Oncology
consultant, England, ID14, scenario 1)
“and she’s got cancer and it’s been shown in multiple
studies that patients with cancer undergoing
treatment either do better or it’s safe to give them low
molecular weight heparin” (Oncology consultant,
England. ID 33, scenario 1)
Again in scenario 2, GPs were more likely to think of
using warfarin than the other doctors.
“But if he refuses to go for investigation for his own
self and he’s able to weigh up the information and
come to an opinion and he has got a capacity to make
that decision, from his point of view, I’ve got no
choice but to start him on Warfarin” (Senior GP,
England, ID28, scenario 2)
In addition, some oncologists and palliative physicians
specifically rejected warfarin as a choice because of the
presence of liver metastases. No GP rejected warfarin in
scenario 2.
“He needs to be started on a low molecular weight
heparin today and with his liver metastases I would
thinking, forget warfarin and just keep him on a
low molecular weight heparin indefinitely”
(Palliative medicine consultant, England, ID4,
scenario 2)
However, in scenario 6, about a patient in the last
few days of life, no doctor recommended warfarin, and
the decision-making then centred on the potential
benefits, burdens and practicalities of LMWH in this
situation.
“. . .avoid injections of Clexane which are in
themselves unpleasant because they have to be
subcutaneous, they can hurt, they can cause bruising,
discomfort in the abdomen”. (Oncology registrar,
England, ID19, scenario 6)
Johnson et al. BMC Medical Informatics and Decision Making 2012, 12:75 Page 6 of 14
http://www.biomedcentral.com/1472-6947/12/75“The fact that his oral intake is variable and he’s
having difficulty swallowing solids also complicates
your choice of anticoagulation, he may not be able to
swallow Warfarin” (Senior GP, England, ID 24,
scenario 6)
Throughout most scenarios, there was a strong em-
phasis on the importance of discussing patient wishes
(nearly three quarters of respondents) as well as a will-
ingness to take advice from other colleagues.
“I mean I think that the patient’s first statement is,
you know, “do whatever” but I actually think that it is
really important that he is involved in the decisions
here because he’s very much sort of towards end of
life now and I wouldn’t recommend for readmission
to hospital and acute treatment of the DVT” (Senior
GP, Wales, ID1, scenario 6)
“So your first question to this patient is, how much do
you want me to do? He’s not refusing all medical
treatment because he’s having prescribed medicines,
so it may well be that he will consider anticoagulation
if a DVT was confirmed, so I would have that first
discussion with the patient about whether he would
want me to investigate or not because if he wasn’t
going to accept any treatment, then clearly there
would be no point in proceeding.” (Oncology
consultant, Wales, ID12, scenario 6)
“I’m thinking this is really difficult and there is the
children involved as well so that does make a difference
about whether you would want the social work team to
be involved and I’d probably speak to my consultant
and maybe a surgeon. Just to find out how risky it is to
put someone on a treatment dose of tinzaparine when
they’ve had hepatic surgery two weeks ago” (Palliative
registrar, England, ID3, scenario 2).
The latter quote also demonstrates how the patient’s
circumstances and the impact of management options
may affect their dependants, are taken into account.
Interview findings
Five themes were derived from the interview data; 1) lo-
gistical & organisational issues (split between investiga-
tion & treatment), 2) ethical frameworks & the concept
of appropriateness, 3) patient & disease specific factors
4) knowledge, evidence & experience which doctors used
to formulate decisions and 5) VTE risk assessment and
prophylaxis. As the research questions related to the
diagnosis and management of established VTE, the find-
ings relating to risk assessment prophylaxis will be
reported elsewhere. The first two themes were keyfactors influencing decisions and will be discussed under
main headings. The impact of themes (3) and (4) -pa-
tient &disease factors, and the evidence &experience of
doctors, is mediated through both of the first two
themes. In view of this, aspects of themes three and four
will be discussed under the two main headings – logis-
tical and organisational issues and the concept of
appropriateness
Theme 1: Logistical & organisational issues
Investigation
The burdens of investigation resulting from logistical
and organisational factors, seemed to be a particular
problem for patients with advanced disease, e.g. al-
though long waits in radiology departments, clinics or
emergency rooms or unnecessary days in hospital are
frustrating for people with better performance status,
they may be better able to cope with the accompanying
physical demands than those with poorer performance
status. There were particular issues related to how easily
accessible the services were for diagnostic tests in par-
ticular. This included how far the patient had to travel,
availability of transport and the availability of ‘same day’
diagnostic test facilities. If the patient was likely to have
to stay overnight in a hospital just to get a particular test
completed for instance, the doctor may not feel that it
was an appropriate choice for them, taking into account
other factors (discussed in further sections).
“. . . in a hospice that’s 3 and a bit miles away from the
local hospital is that if I have somebody here who
might have a DVT or a PE and they’re fit enough to
be investigated and treated, I can’t always access a
service which will diagnose VTE the same day. If I
send the patient up to the hospital accepting that the
patient may stay overnight, there is an issue that
perhaps it won’t be see as urgent because they’ve
arrived and they go in the queue like everybody else
and they might end up staying there 3 or 4 days when
their life expectancy is quite short and I don’t want
them to be spending and they particularly don’t want
to spend time in hospital.” (Palliative medicine
consultant, England, ID18)
“The main difficulty with ambulance transport is the
time that it sometimes takes. . . and quite often things
get escalated to a 999 ambulance because there aren’t
any acute ambulances. So if people haven’t got their own
transport and nobody to take them or you feel they’re
too unstable, that’s rare because we’re a mile away from
the hospital, usually it’s quicker for people and safer for
people to go straight there in private transport than by
ambulance because of the difficult patient transport
because of the time it takes.” (Senior GP, Wales, ID 31)
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tice which minimised disruption to patients. These included
specialised services for testing for VTE, and the employ-
ment of specialist nurses who co-ordinated the VTE and
thromboembolism services across NHS organisations.
“What we’ve done is reconfigured the in-patient base
. . . so I could have said, “well go to [town] Casualty”
and I know that if I send that person to [town]
Casualty anything could happen because you get a
junior doctor not knowing they’ve got cancer or
whatever and probably admitted to a geriatric ward
where 3 days later they do a Doppler ultrasound and
get confused and muddled by all manner of the rest of
her case versus “oh just tell her to come to
[assessment unit].” I’ve rung [assessment unit] and
when she gets to [assessment unit], I said “send her
straight down for a Doppler ultrasound and if it’s
negative send her home and if it’s positive put her on
tinzaparin and send her home.” (Oncology director,
England, ID5)
“I do a clinic on a Thursday over in the main
department at [hospital] and there is a little laminated
sheet stuck on the x-ray box and it says, Suspect a
DVT? Call this number and they do one straight
away. Basically if somebody comes in to your clinic
with a swollen painful leg, you ring that number, you
whizz them round to x-ray and you get a Doppler
there and then, I mean it’s a 9 to 5 service it’s not out
of hours, but yeah it’s easy . . .. “(Oncology consultant,
England, ID24)
“I know some places will have a specialist nurse who
deals with these kind of calls and then organises and
liaises with the radiologist services directly and they
have access to that but they aren’t coming through
the registrar on call handling x number of other calls,
so that takes a bit of a burden off us.” (Oncology
registrar, England, ID10)
The complex balance of the risk of bleeding against
the risk of further VTE (if that is the correct diagnosis)
leads to an urgency with regards to arranging an investi-
gation for some patients. Not all doctors had access to
streamlined investigations and although urgent scans
could be arranged, it took considerable time, often from
the consultant, because this had to be arranged
personally.
“. . . there was a high risk of him having a PE but then
also he has a bleeding in his duodenum so I was
between a rock and a hard place, if I now
anticoagulate him then I might set off a significantgastrointestinal bleed and if I don’t anticoagulate him
and he really is positive for a PE and he might die
from this PE so you are between a rock and a hard
place. But then you overcome that by walking down to
the CT department and telling them the story and
then they put him on the list as soon as ever and you
make a clinical decision. . . and sometimes in terms of
time management that is a little bit difficult.”
(Oncology consultant, England, ID28)
Treatment
Organisational difficulties were also a concern when
optimising treatment, for example, a hospice physician
or oncologist may initiate LMWH, but problems arise
subsequently with ongoing prescription and monitoring
by the GP.
“But I think it’s important that there is good
coordination around that because normally what will
happen is the GP will suddenly find out, oh the
patient is on anticoagulation. But it depends who
they’ve seen in the hospital, it also may not be as clear
as to why they were started on it, how long they need
to be on it, what dose they were started on.”
(Oncology consultant, England, ID12)
Clear tension between the two settings was evident in
some areas. Interview data from oncologists demon-
strated a perception that this may be partly cost-driven
(warfarin is cheaper than LMWH) and was a variable
problem depending on whether the prescribing budget
responsible for LMWH given to patients in the commu-
nity was hospital or community. Difficulties with com-
munity administered LMWH were also discussed by
respondents.
“They [GPs] don’t know how to handle VTE in cancer
patients as well as I do. . . all I will be able to do at
that point, is make it absolutely clear what the
specialist advice is and respect the fact that if
something goes wrong, I will put my hands up and
say, well I made it quite clear that I didn’t want this
patient to be on warfarin and the GP will then have to
defend their decision. It will be a very sad when they
stand up and say, “well I did this because it was
cheaper”.” (Oncology director, England, ID5)
“I’ve had one patient who nearly didn’t get treatment
over a bank holiday weekend because the GP was
refusing to prescribe it . . . we finally managed to get
them a few days’ supply from the GPs. So they almost
didn’t get treated over that weekend. But apart from
that normally it’s just inconvenience rather than
another dangerous thing like that. . .It’s happened 2 or
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think other consultants have had problems.”
(Oncology consultant, Wales, ID22)
“They can rush around all day long district nurses
doing tasks, taking bloods, giving [LMWH] injections.
They can’t be doing everything else. . .all the other
things that district nurses can’t do if they spend three
quarters of an hour driving to a patient giving an
injection, driving back, everyday. That’s actually a
massive cost, not financial cost. Cost in terms of real
limited number of nurses. If relatives and patients can
be taught to give injections themselves, I would favour
that because I think it’s massive, massive if you really
live somewhere rural.” (Palliative medicine doctor,
England, ID6)
Theme 2: The concept of appropriateness
The concept of appropriateness; whether doctors consid-
ered it ethically appropriate to investigate or treat the
patient for VTE, was a major theme arising from the
interview data. In this paper we provide an overview of
the key issues arising from this theme. As it was an im-
portant and complex area of debate we will be reporting
the results of this theme in detail subsequently.
The concept of appropriateness was inextricably linked
with expected patient prognosis and availability of ap-
propriate services; doctors were more willing to investi-
gate and treat those with a good prognosis or where
services were easily accessible. There was debate about
how appropriate it was for LMWH to be administered
to a patient thought to be in the last few days/weeks of
life and if these patients should be moved for
investigation.
“I guess the other issue, which I don’t know if it’s a
barrier particularly, but it’s certainly a poorer
prognosis end of things, how appropriate it is to treat
problems, particularly in somebody who is
approaching end of life care and certainly in the last
few days of life.” (Oncology consultant, England, ID7)
“So it’s not that they’re nearing the end of life because of
a clot, they’re nearing the end of life because of their
disease. If that’s happening anyway you have to think
about the burden of the investigation and the treatment”
(Palliative medicine consultant, Wales, ID 25)
The importance of assessing each patient’s situation
individually with regard to likely benefit within the
expected prognostic timeframe, balancing against un-
necessary interventions in the last few hours/days of life
was highlighted. For example, if a patient has had benefit
from anticoagulation, or has had recurrent problemswith VTE, then the threshold for treating would be
lower for longer.
“But I think it is again very hard to sort of say, to
come up with a general rule. . . ., if they seem to be
getting recurrent PEs or they’ve had very difficult to
manage sort of swollen limbs as a result of
thromboembolic problems etc., that has in the past
appeared to be managed better by actively managing
it, then that would influence you to give it a go until
such time that it became apparent that it was no
longer appropriate if they were in the sort of
unconscious phase, you know, dying within hours to
short days.” (Oncology consultant, England, ID 18)Summary of main issues
We set out to explore the influences affecting the way
doctors made clinical decisions in this complex clinical
situation, and to discover the barriers and facilitators to
best practice, in particular, with regard to the prescrip-
tion of LMWH rather than warfarin.
We identified two main areas of decision making in
our data which related to the investigation and manage-
ment of VTE. Within these decisions, the impact of or-
ganisational factors, the considered appropriateness of
an intervention (investigation or treatment), estimated
patient prognosis and the perceived benefits/burdens of
LMWH compared with warfarin influenced doctors’
decisions. Barriers and facilitators to implementation of
treatment guidelines were demonstrated within all these
influences.Discussion
A range of issues were reported by participants to influ-
ence their diagnosis and management of VTE in people
with advanced, unless the patient was considered to be
imminently dying, in which the decision making
appeared to be more straightforward.
Many of these factors interweave and are themselves
influenced by and dependent on each other. It is only
after all are taken into account, resulting in an assess-
ment of whether any further action is appropriate for
that individual patient, that the doctor arrives at the
point of referring the patient for investigation or starting
empirical treatment with LMWH.Barriers and facilitators to evidence based practice
Logistical and organisational
There were a number of logistical and organisational
factors that influenced whether or not patients with can-
cer and suspected VTE were investigated, as well as
whether or not they subsequently received treatment.
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Issues relating to the practicalities of investigation and
treatment were considered a problem, this may result in
the patient not being investigated at all, or being given
empirical LMWH, thus exposing the patient to the risk
of bleeding for a condition they might not have. At
present, smooth streamlined services do not appear to
be consistently provided across the areas explored, and
the brunt of the adverse effects are likely to be borne by
these vulnerable patients with advanced disease who
already have a multitude of problems. The decision to
investigate and treat patients who would benefit should
be unaffected by inadequate organisation of the health
care system.
Examples of good practice, where oncology centres
had the process of organising investigations, results and
treatment showed how the impact of these aspects could
be minimised. However, these service improvements are
not consistent and there is little in the published litera-
ture regarding successful service models in this field. In
addition, there was no example where the problems aris-
ing from ambulance transport inflexibility had been
overcome.
A variety of factors may act as barriers or facilitators
to the implementation of service improvements; finan-
cial incentives or penalties, media interest, competing
priorities and the presence of local champions.LMWH prescription and monitoring
Participants in our study referred to LMWH prescrip-
tion more often than we had anticipated from national
figures of long term LWMH, however, this may be due
to the regional influence of SN, MJ and AM who were
mentioned in some interviews as opinion leaders, and
this may not be reflected across the UK.
Good systems between primary and secondary care
are important. It was noted that warfarin was sometimes
prescribed in the community. This use of a treatment
largely superseded by LWMH may be because GPs had
less experience of cancer-related VTE, seeing far fewer
patients per year compared with palliative physicians
and oncologists. This problem is likely to be more than
merely a lack of knowledge, and nationally, the low level
of LMWH prescribing is unlikely to be solely explained
by GP prescription of warfarin. Evidence based protocols
for the funding and shared clinical responsibility be-
tween secondary and primary care for therapeutic inter-
ventions which may not be initiated in primary care, but
for patients whose care is largely in the community may
be helpful in resolving the tension. Given that these
patients may also be seen by hospice services, it is im-
perative that clear boundaries of prescribing and moni-
toring responsibility are set. Examples of shared careprotocols regarding LMWH do exist [28,29] but again,
this is not consistent.
Implications for practice and service delivery
Our study findings suggest a number of service develop-
ments that might improve adherence to current guide-
lines and improve quality of care. Patients with
advanced disease need to be able to access appropriate
clinical tests in a timely manner. Examples of innovative
diagnostic and management services should be widely
shared, especially same-day diagnostic services. Ambu-
lance services could be given feedback about the need
for flexibility, and swift, timely transportation and the
availability and funding of DVT nurse specialists to
streamline diagnostic and treatment processes
encouraged.
Good practice with regard to shared care prescribing
and monitoring protocols for LMWH treatment across
primary and secondary care settings should be supported
and disseminated so that patients will not be prescribed
warfarin inappropriately on the grounds of cost or inex-
perience and lack of knowledge. Change in practice is a
complex issue and it is perhaps not surprising therefore,
that simply issuing guidelines has not been successful in
achieving high rates of prescribing of LMWH. For the
most part, we have not found major deficits in knowledge
– which guidelines might help. Rather, we have found a
complex interplay of structural, process and patient/phys-
ician factors which may also need to be considered if ap-
propriate management of VTE is to be achieved.
Future research
This study did not directly seek the opinion of patients
themselves. It is therefore vital that this is explored to
find out what patients consider to be important with re-
gard to successful management of VTE. The develop-
ment of patient relevant outcomes is key to any further
research in this area.
It is clear from our data, that many of the difficulties
in decision making come from the fact that the evidence
base underpinning the current management guidelines
was developed in patients with a much greater perform-
ance status. Thus it can be difficult to extrapolate that
information to inform the management of the person
attending in clinic. Hence it is important to address the
evidence gaps in this area of VTE research in order to
provide more specific guidance for clinicians managing
palliative care patients, including gaining an understand-
ing of the natural history of VTE in people with
advanced disease so that the risk-benefit balance of
LMWH anticoagulation may be better assessed. Further
research into whether, and how, patients are involved in
decision making about the diagnosis and management of
VTE would also be helpful.
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The purpose of the think aloud is to reveal cognitive ac-
tivities in handling the individual case scenarios and thus
we were able to look only at one set of decisions at a
point in time. An exploration of how decisions evolve
over time would be interesting, but need different types
of case scenarios.
Doctors volunteering to participate in this study may
be those with more interest in this topic for several rea-
sons: previous experience of difficulties, a raised aware-
ness of the issue as a result of working in the same
geographical area as a co-author (SN in Wales, MJ and
AM in the North of England), an approach to clinical
practice that is committed to contributing to the evi-
dence base, and therefore may not be representative. As
the pool of potential oncologists and palliative physicians
was far fewer than the GPs this is likely to be a particu-
lar issue for the GP group, and may be one reason why
some of the accounts from oncologists regarding conflict
with GPs over management with long-term LMWH are
not mirrored in the GP interviews. Although GPs were
the professional group more likely to use warfarin rather
than LMWH, the GP participants in the study often re-
ferred to taking the advice of oncologists over the
patient’s management. It is possible that even if the par-
ticipant accepted that the think aloud was not a test,
they may have revised the subject of venous thrombo-
embolism and cancer prior to the interview.
If one of the co-authors was known to a participant, it
is possible that they may have responded with what they
thought was the “correct” answer if this differed to their
usual practice. The use of a non-clinical researcher and
anonymity were used to reduce this risk. Furthermore,
to ensure our promise of strict confidence, co-authors
did not have access to complete transcripts of interviews
conducted with their colleagues. This was to ensure that
colleagues could not be identified by personal opinions
or clinical examples given which may allow possible
identification of participants by co-authors to occur.”
However, none of these issues affect the importance of
the experience of the doctors interviewed, and as many
of the same issues were raised in both of the geograph-
ical areas sampled in this study it is likely that they mir-
ror problems encountered nationally.
Conclusions
Doctors find making decisions about the diagnosis and
treatment of people with VTE and advanced cancer com-
plex, with little published data based on these patients to
guide practice. Complexities arise because of the risk-
benefit balance of anticoagulation in patients who are at
high risk of recurrent VTE and bleeding. This requires a
judgement of appropriateness in the context of benefits
and burdens within the timeframe of estimated prognosis.Influences on such judgements are inherently contextual
and individual both to the patient and doctor.
Logistical issues regarding diagnosis (arranging investi-
gation, transport, avoidance of inappropriate time in
hospital) and management (prescribing, monitoring and
budgetary responsibility for LMWH, cross-sector team
working) add to the complexity. Given the barriers to
and the complexity of decision-making that we have
found in this area, simple rejoinders to follow evidence
are unlikely to succeed in isolation. If we want to im-
prove practice we need to develop carefully considered
strategies that address the barriers which result, not only
from lack of knowledge, but also from poorly organised
services and inadequate understanding of patient prior-
ities for the management of VTE in advanced cancer.
Appendix A. CODING FRAMEWORK FOR THINK
ALOUD INTERVIEWS
Principles
1. Coding generally to take place at the level of the
sentence.“you need to check what her full blood count is to see if
she is anaemic and you maybe able to improve her
breathlessness by treating that” would be coded as both
plan and reason but coded separately this would be:
“you need to check what her full blood count is to
see if she is anaemic”
(Plan)
“and you maybe able to improve her breathlessness
by treating that” (reason)
2. Double or triple code rather than split up sentences
to keep context intact. Examples:
3. When obtaining the retrieved segments at the end of
analysis, the ‘reason’ example given above will be
meaningless without the plan with which it relates to
4. Two or more of the same operators in the same
sentence are to be coded differently if it’s an
unrelated topic.
5. A significantly longer sentence than usual can be
coded as parts of the sentence
Codes
1. COLLECT
Questions which the participant asks to inform their
thinking:
Example: “why has she not had a hysterectomy?”
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information:
Example: “I also need to know about the set up at home
and if she has had any oxygen or breathing assessment or
even any support from the district nurses or the GP or
that she is known to another member of my team”.
2. INTERPRET
Stating what the information infers / means, clinically
Example: “His examination was essentially normal
although he is a little bit hypertensive and slightly
tachycardic”
Example: “He’s just had a recent operation. He’s 54,
he’s a man. He’s got risk factors for heart disease as
well conceivably”
Rephrasing of the data
3. EVALUATE (Clinical or social)
Making clinical judgements based on the data that is
not a diagnosis or goal
Example: I mean if he had a D-dimer that would
probably be a bit of a waste of time because it’s likely
to be raised anyway”
Example: “I think he’s got fairly end stage disease and so
I wouldn’t push any detailed investigations on him at all”
(this would be double coded with ‘reason’)
Making social judgements based on the data that is
not a diagnosis or goal
Example: “I’m thinking that this man is, you know, has
obviously got again a poor prognosis but his health beliefs
are probably maybe not quite in keeping with the extent
of his disease or, you know, what his disease is like.”
If it’s not an obvious judgement then should be coded
under Interpret.
The difference between Interpret and Evaluate – when
participants are interpreting, they are usually doing some-
thing basic and simple with the data presented to them but
Evaluation is one step further on in that they are saying
something about the data which is a judgement. Here is a
good example:
“So basically he’s only 2 weeks post-major op, so he
actually shouldn’t be driving himself anywhere”The first half of this sentence is Interpretation.
The participant has taken from the scenario that the
patient is 2 weeks after a major operation. The sec-
ond half is Evaluation as “so he actually shouldn’t be
driving himself anywhere” is a social judgment about
the patient’s right to drive so soon after having a
major operation.
There are two distinct processes in reasoning:
Interpreting – where the respondent is looking at
the information and interpreting it to make sense
of it.
Evaluate – where the respondent is taking the infor-
mation and making some form of judgement/diagnosis
on the basis of it
4. DIAGNOSE
A firm statement which pinpoints a specific diagnosis.
Example: “You’ve done the scan and she’s got clots. . .I
mean she’s got pulmonary emboli”
Include any medical diagnosis, does not specifically
have to be VTE or cancer related
5. OPINION
Participant offers their own personal opinion on
scenario
Example: “It’s normally the sort of thing that happens
on a Friday afternoon in a surgery at five o’clock when
everyone else has gone home”
Or how they would act if in patients position
Example: “His choice to decline chemotherapy, fine,
that is what I would do”
6. PERSONAL KNOWLEDGE
Procedures / tests / symptoms etc. which participants’
state they know about
Example: “Well progesterone does give you an
increased risk of PEs as well”Their previous experience with other patients:
Example: “I’ve met people with endometrical
carcinoma who have got lung mets or they might
have infusions or may have another underlying
condition”.
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not interpretation or evaluation. Quotation of study
results or statistics:
Example: “excising liver mets can extend survival by
five years by about forty percent”
7. PLAN
Any future plan related to management or treatment.
Example: “You’ve got to deal with the immediate
situation which is that she is breathless and you have
got a way of making her not breathless”
Include discussing future treatment with the patient
Example: “we would explain the results of the scan to
her and then explain what the treatment would
involve, that it’s a daily injection”
Include speculative plans
Example: “or you could put her on warfarin which
would require blood tests and alter her doses”
8. REASON
Any verbalisation which relates to why a participant
has chosen a course of action
Example: [rationale for prescribing LMWH] “and also
more importantly it may prevent her having a fatal
pulmonary emboli in the meantime”
NOT related to the reason why they have stated a spe-
cific diagnosis.
NOT related to the reason why they think a patient
may have chosen a course of action.
9. PREDICT
What may happen if the participant chooses a course
of action or what may happen if they do nothing
Example: “. . .but right now if you don’t do anything he
will be dead”10. GOAL
The final aim of all the participant’s planning. Would usu-
ally be related to anticoagulation but could be to sendpatient for a scan/ test or to refer to another clinician e.g.
consultant for trainees or oncologist for GPs etc.
Example: “I would want her to have Clexane”
Example: “I’d just keep him on enoxaparin
indefinitely”
11. BARRIERS re LMWH.
As this is the central focus of the study, these need to
be noted. These barriers need to be flagged up to in-
form the topic guide for part 2 so it’s essential we get
to them straight away.
Include barriers to generic “anticoagulation”
Include comments re warfarin if relevant as will help
with topic guide
Appendix B. Scenario summaries
Scenario 1
A 68 year old single lady has endometrial carcinoma.
She has mild but continuous vaginal bleeding. She feels
she would not be able to cope if the bleeding became
any worse. She presents to the clinic with a 3 month his-
tory of progressive breathlessness such that she now
cannot walk across her small lounge to the bathroom
without severe breathlessness. A ventilation-perfusion
scan shows multiple pulmonary emboli.
Scenario 2
A 38 year self employed man has colorectal cancer with
recently resected hepatic metastases. His wife is away at
the moment and he is at home with a 3 year old and a 5
year old. His sister has agreed to come up and help on
Friday (it is now Monday). He lives in a small village “off
the beaten track”, has not been there very long and
doesn’t know the neighbours well.
This morning he woke to find his left leg swollen and
painful, making it quite difficult to walk. He took a taxi
to the surgery as his leg was too painful to let him drive,
bringing the children with him. He will not leave the
children with anyone else (even if he could find anyone
else) so is refusing to go for investigation or admission.
He will only leave the children once his sister comes on
Friday.
Scenario 5
A 69 year old lady has an extensive small cell lung can-
cer with newly diagnosed brain metastases. She is due to
receive palliative whole brain radiotherapy the following
week but now presents with sudden onset breathlessness
and pleuritic right side chest pain.
On examination she is short of breath at rest with a
tachycardia of 100, BP 100/76, her JVP is raised and she
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and right pulmonary arteries.Scenario 6
A 52 year old man has extensive unresectable
oesophageal cancer with hepatic and bone metastases.
He now spends all day in bed. During a recent hospice
admission he was found to have a corrected calcium
of 3.4 mmol/l and was successfully treated with intra-
venous fluids and bisphosphonate. A syringe driver
was commenced at the hospice and continues since
oral intake is variable. He has developed a painful
swelling in his left leg.
He is cachectic with sacral oedema. Cardiovascular
and respiratory examinations unremarkable but abdom-
inal examination reveals tender hepatomegaly with a
small amount of ascites. His left leg is grossly swollen,
tender and erythematous to the thigh.
He is lucid but weak, saying, “Do whatever you think
is best doctor”. Has previously stated he would like to
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